Atezolizumab

Description

Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity.

Medicine classification

ATC Code
Title
Class
L01FF05
Atezolizumab
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors

Medicines

Drug
Countries
TECENTRIQ

Australia Austria Canada Cyprus France

Product monographs

Monograph
Type
Country
TECENTRIQ Concentrate for solution for infusion
MPI, EU: SmPC

Unique Ingredient Identifier (UNII)

52CMI0WC3Y - ATEZOLIZUMAB

SNOMED-CT

719371003 - Atezolizumab (substance)

Usage: Next >